Amgen buys DeCode Genetics for $415 million
THOUSAND OAKS, Calif. — Amgen is buying an Iceland-based biotech company for $415 million, the two said Monday.
Amgen announced it would acquire DeCode Genetics, based in Reykjavik, Iceland, in a deal that Amgen’s board of directors unanimously approved. Founded in 1996, DeCode focuses its business on finding links between the human genome and disease susceptibility. The acquisition is expected to close before the end of 2012 and does not require regulatory approval.
"DeCode Genetics has built a world-class capability in the study of the genetics of human disease," Amgen president and CEO Robert Bradway said. "This capability will enhance our efforts to identify and validate human disease targets. This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets."
No comments found
Giant-Carlisle participates in GSK inhaler recycling program
CARLISLE, Pa. — Several stores in the Giant Food Stores chain will collect used respiratory inhalers under a program sponsored by drug maker GlaxoSmithKline, the supermarket chain said.
Giant, an Ahold-owned banner also known as Giant-Carlisle to distinguish it from fellow Ahold banner Giant Food of Landover, Md., said 48 stores in Pennsylvania would participate in GSK’s "Complete the Cycle" recycle program for respiratory inhalers used to treat asthma, chronic obstructive pulmonary disease, allergies and flu.
Customers at Giant who receive a prescription for a GSK inhaler will have a sticker placed on the inhaler box stating that it can be returned for recycling at the pharmacy.
"This recycling program is an opportunity for our customers to safely dispose of their inhalers at our friendly pharmacies," Giant-Carlisle director of pharmacy operations Leigh Shirley said. "As a company, Giant is always looking for ways to minimize our impact on the environment whether it be in our stores, on the roads or in our distribution centers."
No comments found
FDA grants Astellas NDA for tacrolimus extended-release capsules
NORTHBROOK, Ill. — Astellas Pharma US announced the Food and Drug Administration’s review of their new drug application for tacrolimus extended-release capsules, a once-daily formulation of the calcineurin-inhibitor immunosuppressant tacrolimus, for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.
The NDA submission is based on six randomized and comparative studies of 2,842 (1,689 tacrolimus extended-release) kidney transplant recipients and 689 (393 tacrolimus extended-release) liver transplant recipients conducted in the United States, Canada, Europe, Australia, Brazil and New Zealand, among other sites. Based upon the September receipt of the NDA submission, the FDA Prescription Drug User Fee Act review date will be July 21, 2013.
"The NDA acceptance for tacrolimus extended-release capsules marks an important step toward addressing the unmet treatment need for transplant recipients who have difficulty controlling their immunosuppression drug levels with existing products," said Roy First, Astellas Global Therapeutic Area Head for Transplantation. "Astellas has been committed to the field of immunology for more than 20 years and plans to continue that commitment by working to bring promising new treatments for patients to market."
Astellas US is a subsidiary of Tokyo-based Astellas Pharma, a pharmaeutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
The NDA submission is based on six randomized and comparative studies of 2,842 (1,689 tacrolimus extended-release) kidney transplant recipients and 689 (393 tacrolimus extended-release) liver transplant recipients conducted in the United States, Canada, Europe, Australia, Brazil and New Zealand, among other sites. Based upon the September receipt of the NDA submission, the FDA Prescription Drug User Fee Act review date will be July 21, 2013.sms lån